锐客网

  1. 首页 > 生活杂烩 > 健康 > >

乳腺癌|盘点 2020｜马飞教授：乳腺癌治疗新进展( 十 )


[41]SLEDGE G W J R, TOI M, NEVEN P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial[J]. JAMA Oncol, 2019, 6(1):116-124.
[42]NEVEN P, JOHNSTON S R D, TOI M, et al. MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer[J]. J Clin Oncol, 2020, 38(15_suppl):1061-1061.
[43]HAMILTON E P, CORTéS J, OZYILKAN O, et al. 273O nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer[J]. Ann of Oncol, 2020, 31:S348.
[44]RAZAVI P, CHANG M T, XU G, et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers[J]. Cancer Cell, 2018, 34(3):427-438.
[45]MOSELE F, STEFANOVSKA B, LUSQUE A, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer[J]. Ann Oncol, 2020, 31(3):377-386.
[46]ANDRé F, CIRUELOS E, RUBOVSZKY G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer[J]. N Engl J Med, 2019, 380(20):1929-1940.
[47]ANDRé F, CIRUELOS E M, JURIC D, et al. LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)[J]. Ann Oncol, 2020, 31:S1150-S1151.
[48]RUGO HS, LEREBOURS F, CIRUELOS E, et al. Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results[J]. J Clin Oncol, 2020, 38(15_suppl):1006-1006.
[49]RUGO H S, LEREBOURS F, JURIC D, et al. PD2-07 Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results[OL]. (2020-12-09)[2020-12-15]. https://www.abstractsonline.com/pp8/#!/9223/presentation/787.
[50]WANDER S A, JURIC D, SUPKO J G, et al. Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC)[J]. J Clin Oncol, 2020, 38(15_suppl):1066-1066.
[51]TOPALIAN S L, DRAKE C G, PARDOLL D M. Immune checkpoint blockade: a common denominator approach to cancer therapy[J]. Cancer Cell, 2015, 27(4):450-461.
[52]PETKOV V I, MILLER D P, HOWLADER N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study[J]. NPJ Breast Cancer, 2016, 2:16017.
[53]SCHMID P, ADAMS S, RUGO H S, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer[J]. N Engl J Med, 2018, 379(22):2108-2121.
[54]HARBECK N, ZHANG H, BARRIOS C H, et al. LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)[J]. Ann Oncol, 2020, 31:S1144.
[55]EMENS L A, ADAMS S, BARRIOS C H, et al. LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer[J]. Ann Oncol, 2020, 31:S1148.
[56]MILES D W, GLIGOROV J, ANDRé F, et al. LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)[J]. Ann Oncol, 2020, 31:S1147-S1148.

推荐阅读


上一篇：减肥|减肥期间，养成这几个好习惯，坚持3个月，让体重不知不觉下降

下一篇：医院|【医疗】中国太平首家康复医院今日在沪投入试运行